The European Commission has approved BRAFTOVI in combination with cetuximab [...]

Lonza has entered an exclusive licensing agreement with Antharis Therapeutics [...]

Faeth Therapeutics has launched as a publicly traded oncology company [...]

Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

Context Therapeutics has reported encouraging interim Phase 1 data for [...]

oryzon-iadademstat-aml-alice2-frida-eha-2026 Oryzon Genomics has reported updated Phase 1b data from [...]

Sygnature Discovery has entered into a strategic collaboration with AI [...]

Poolbeg Pharma has presented two posters at the European Hematology [...]

Poolbeg Pharma has activated the first clinical site and begun [...]

PhoreMost has unveiled its lead oncology programme, PMC-001, as the [...]